Is there a Bearish outlook for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) this week?

July 27, 2018 - By Catherine Diaz

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) LogoInvestors sentiment decreased to 0.97 in 2018 Q1. Its down 0.25, from 1.22 in 2017Q4. It fall, as 31 investors sold Sarepta Therapeutics, Inc. shares while 81 reduced holdings. 45 funds opened positions while 64 raised stakes. 54.74 million shares or 3.52% more from 52.88 million shares in 2017Q4 were reported.
Morgan Stanley holds 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 522,584 shares. Moreover, Riggs Asset Managment Communication has 0% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Putnam Ltd Liability, a Massachusetts-based fund reported 23,832 shares. Mackay Shields Ltd Liability Corporation invested in 0.01% or 20,894 shares. Driehaus Capital Management Ltd Liability Co has 54,529 shares. Stonebridge Cap stated it has 0.08% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Barclays Public Ltd Company owns 45,639 shares for 0% of their portfolio. Voya Investment Limited Com holds 0.06% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) or 365,695 shares. Axa has invested 0.02% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). The Ontario – Canada-based Td Asset Inc has invested 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Crow Point Ptnrs Ltd has invested 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Utd Cap Advisers has 26,111 shares for 0.01% of their portfolio. Qs Ltd Llc holds 0% or 2,664 shares. Stifel Fincl stated it has 33,436 shares or 0.01% of all its holdings. Creative Planning owns 86,850 shares.

Since June 27, 2018, it had 0 insider purchases, and 2 insider sales for $14.41 million activity. Barry Richard sold 75,000 shares worth $9.78M.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 17 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 15 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. Sarepta Therapeutics has $267 highest and $60.0 lowest target. $148.43’s average target is 18.56% above currents $125.19 stock price. Sarepta Therapeutics had 31 analyst reports since January 31, 2018 according to SRatingsIntel. Morgan Stanley downgraded the stock to “Equal-Weight” rating in Wednesday, March 21 report. The firm earned “Buy” rating on Monday, March 12 by Piper Jaffray. The rating was maintained by JP Morgan with “Overweight” on Wednesday, February 21. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Outperform” rating given on Tuesday, March 13 by Credit Suisse. The rating was maintained by Piper Jaffray on Friday, February 9 with “Buy”. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Equal-Weight” rating by Morgan Stanley on Friday, May 4. The rating was maintained by H.C. Wainwright on Monday, March 12 with “Buy”. On Thursday, May 3 the stock rating was downgraded by Oppenheimer to “Hold”. Leerink Swann maintained the stock with “Outperform” rating in Tuesday, March 13 report. The firm earned “Buy” rating on Friday, March 2 by Piper Jaffray. Below is a list of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) latest ratings and price target changes.

21/06/2018 Broker: Robert W. Baird Rating: Buy New Target: $202.0000 Maintain
21/06/2018 Broker: Nomura Old Rating: Buy New Rating: Buy Old Target: $131 New Target: $205 Maintain
20/06/2018 Broker: WBB Securities Rating: Buy Maintain
20/06/2018 Broker: Cowen & Co Rating: Buy New Target: $178.0000 Maintain
20/06/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $91 New Target: $163 Maintain
20/06/2018 Broker: Barclays Capital Rating: Buy New Target: $180.0000 Maintain
20/06/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $121 New Target: $196 Maintain
19/06/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy Old Target: $96 New Target: $267 Maintain
15/06/2018 Broker: BTIG Research Rating: Buy New Target: $120 Initiates Coverage On
05/06/2018 Broker: Nomura Rating: Buy New Target: $131.0000 Maintain

The stock decreased 4.60% or $6.03 during the last trading session, reaching $125.19. About 1.50M shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 197.08% since July 27, 2017 and is uptrending. It has outperformed by 184.51% the S&P500.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $8.20 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Globenewswire.com which released: “Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)” on June 29, 2018, also Marketwatch.com with their article: “Sarepta stock drops after Muscular Dystrophy study halted by FDA” published on July 25, 2018, Nasdaq.com published: “Sarepta Therapeutics to Announce Second Quarter 2018 Financial Results and Recent Corporate Developments on …” on July 20, 2018. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: Fool.com and their article: “3 Best Gene Therapy Stocks of 2018 (So Far)” published on July 03, 2018 as well as Benzinga.com‘s news article titled: “Sarepta’s Clinical Hold Could Be A Solid Biosciences Catalyst, Says Bullish Chardan Analyst” with publication date: July 26, 2018.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.